Oncology Pharma Stock Buy Hold or Sell Recommendation
| ONPH Stock | USD 0.0001 0.00 0.00% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Oncology Pharma is 'Strong Sell'. The recommendation algorithm takes into account all of Oncology Pharma's available fundamental, technical, and predictive indicators you will find on this site.
Check out Oncology Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Oncology and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Oncology Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Oncology |
Execute Oncology Pharma Buy or Sell Advice
The Oncology recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Oncology Pharma. Macroaxis does not own or have any residual interests in Oncology Pharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Oncology Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Solid | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Oncology Pharma Trading Alerts and Improvement Suggestions
| Oncology Pharma is way too risky over 90 days horizon | |
| Oncology Pharma has some characteristics of a very speculative penny stock | |
| Oncology Pharma appears to be risky and price may revert if volatility continues | |
| Oncology Pharma currently holds 205.9 K in liabilities. Oncology Pharma has a current ratio of 0.86, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Oncology Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Oncology Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncology Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncology to invest in growth at high rates of return. When we think about Oncology Pharma's use of debt, we should always consider it together with cash and equity. |
Oncology Pharma Returns Distribution Density
The distribution of Oncology Pharma's historical returns is an attempt to chart the uncertainty of Oncology Pharma's future price movements. The chart of the probability distribution of Oncology Pharma daily returns describes the distribution of returns around its average expected value. We use Oncology Pharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Oncology Pharma returns is essential to provide solid investment advice for Oncology Pharma.
| Mean Return | 89.29 | Value At Risk | -100 | Potential Upside | 1,000.00 | Standard Deviation | 50.01 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Oncology Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Oncology Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Oncology Pharma or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Oncology Pharma's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Oncology pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 88.39 | |
β | Beta against Dow Jones | -13.12 | |
σ | Overall volatility | 302.13 | |
Ir | Information ratio | 0.30 |
Oncology Pharma Volatility Alert
Oncology Pharma is showing large volatility of returns over the selected time horizon. Oncology Pharma appears to be a penny stock. Although Oncology Pharma may be, in fact, a solid short-term or long term investment, many penny pink sheets are speculative investment instruments that are often subject to artificial stock promotion and campaigns of hype which may lead to misinformation and misrepresentation. Please make sure you fully understand upside potential and downside risks of investing in Oncology Pharma or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswing without any event/news,and sudden news releases. We also encourage traders to check biographies and work history of company President, CEO or other officers before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Oncology instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Oncology Pharma Fundamentals Vs Peers
Comparing Oncology Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Oncology Pharma's direct or indirect competition across all of the common fundamentals between Oncology Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Oncology Pharma or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Oncology Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Oncology Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Oncology Pharma to competition |
| Fundamentals | Oncology Pharma | Peer Average |
| Profit Margin | 18.21 % | (1.27) % |
| Operating Margin | (1.42) % | (5.51) % |
| Current Valuation | 756.68 K | 16.62 B |
| Shares Outstanding | 1.16 M | 571.82 M |
| Price To Sales | 66.28 X | 11.42 X |
| Revenue | 10.21 K | 9.43 B |
| Gross Profit | 10.21 K | 27.38 B |
| EBITDA | (8.65 K) | 3.9 B |
| Net Income | 186.03 K | 570.98 M |
| Cash And Equivalents | 3.21 K | 2.7 B |
| Total Debt | 205.9 K | 5.32 B |
| Current Ratio | 0.88 X | 2.16 X |
| Cash Flow From Operations | 7.06 K | 971.22 M |
| Number Of Employees | 5 | 18.84 K |
| Beta | 0.0506 | -0.15 |
| Market Capitalization | 756.68 K | 19.03 B |
| Total Asset | 198.59 K | 29.47 B |
| Z Score | 1.8 | 8.72 |
| Net Asset | 198.59 K |
Oncology Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Oncology . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 9223372 T | |||
| Day Median Price | 1.0E-4 | |||
| Day Typical Price | 1.0E-4 | |||
| Price Action Indicator | 1.0E-4 | |||
| Relative Strength Index | 52.64 |
About Oncology Pharma Buy or Sell Advice
When is the right time to buy or sell Oncology Pharma? Buying financial instruments such as Oncology Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Oncology Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Utilities ETFs Thematic Idea Now
Utilities ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Utilities ETFs theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Oncology Pink Sheet
Oncology Pharma financial ratios help investors to determine whether Oncology Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncology with respect to the benefits of owning Oncology Pharma security.